178 related articles for article (PubMed ID: 32780555)
1. Deficiency of plasminogen activator inhibitor-2 results in accelerated tumor growth.
Westrick RJ; Røjkjaer LP; Yang AY; Roh MH; Siebert AE; Ginsburg D
J Thromb Haemost; 2020 Nov; 18(11):2968-2975. PubMed ID: 32780555
[TBL] [Abstract][Full Text] [Related]
2. Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma.
Eitzman DT; Krauss JC; Shen T; Cui J; Ginsburg
Blood; 1996 Jun; 87(11):4718-22. PubMed ID: 8639841
[TBL] [Abstract][Full Text] [Related]
3. Tumor cell-expressed SerpinB2 is present on microparticles and inhibits metastasis.
Schroder WA; Major LD; Le TT; Gardner J; Sweet MJ; Janciauskiene S; Suhrbier A
Cancer Med; 2014 Jun; 3(3):500-13. PubMed ID: 24644264
[TBL] [Abstract][Full Text] [Related]
4. Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice.
Almholt K; Nielsen BS; Frandsen TL; Brünner N; Danø K; Johnsen M
Oncogene; 2003 Jul; 22(28):4389-97. PubMed ID: 12853975
[TBL] [Abstract][Full Text] [Related]
5. Enhanced venous thrombus resolution in plasminogen activator inhibitor type-2 deficient mice.
Siefert SA; Chabasse C; Mukhopadhyay S; Hoofnagle MH; Strickland DK; Sarkar R; Antalis TM
J Thromb Haemost; 2014 Oct; 12(10):1706-16. PubMed ID: 25041188
[TBL] [Abstract][Full Text] [Related]
6. Molecular competition between plasminogen activator inhibitors type -1 and -2 for urokinase: Implications for cellular proteolysis and adhesion in cancer.
Lobov S; Ranson M
Cancer Lett; 2011 Apr; 303(2):118-27. PubMed ID: 21316840
[TBL] [Abstract][Full Text] [Related]
7. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1.
Gutierrez LS; Schulman A; Brito-Robinson T; Noria F; Ploplis VA; Castellino FJ
Cancer Res; 2000 Oct; 60(20):5839-47. PubMed ID: 11059781
[TBL] [Abstract][Full Text] [Related]
8. The role of plasminogen activator inhibitor-2 in pneumococcal meningitis.
Teske NC; Engelen-Lee JY; Dyckhoff-Shen S; Pfister HW; Klein M; van de Beek D; Kirschning CK; Koedel U; Brouwer MC
Acta Neuropathol Commun; 2022 Oct; 10(1):155. PubMed ID: 36309755
[TBL] [Abstract][Full Text] [Related]
9. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
Jänicke F; Pache L; Schmitt M; Ulm K; Thomssen C; Prechtl A; Graeff H
Cancer Res; 1994 May; 54(10):2527-30. PubMed ID: 8168072
[TBL] [Abstract][Full Text] [Related]
10. The serine protease inhibitor serpinB2 binds and stabilizes p21 in senescent cells.
Hsieh HH; Chen YC; Jhan JR; Lin JJ
J Cell Sci; 2017 Oct; 130(19):3272-3281. PubMed ID: 28794016
[TBL] [Abstract][Full Text] [Related]
11. [The urokinase-type plasminogen activator system and its role in tumor progression].
Kugaevskaya EV; Gureeva TA; Timoshenko OS; Solovyeva NI
Biomed Khim; 2018 Nov; 64(6):472-486. PubMed ID: 30632975
[TBL] [Abstract][Full Text] [Related]
12. Is there a role for urokinase-type plasminogen activator inhibitors as maintenance therapy in patients with ovarian cancer?
van Dam PA; Coelho A; Rolfo C
Eur J Surg Oncol; 2017 Feb; 43(2):252-257. PubMed ID: 27345498
[TBL] [Abstract][Full Text] [Related]
13. Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor.
Zheng Q; Tang ZY; Xue Q; Shi DR; Song HY; Tang HB
J Cancer Res Clin Oncol; 2000 Nov; 126(11):641-6. PubMed ID: 11079728
[TBL] [Abstract][Full Text] [Related]
14. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size.
Abe J; Urano T; Konno H; Erhan Y; Tanaka T; Nishino N; Takada A; Nakamura S
Cancer; 1999 Dec; 86(12):2602-11. PubMed ID: 10594855
[TBL] [Abstract][Full Text] [Related]
15. The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis.
Brungs D; Chen J; Aghmesheh M; Vine KL; Becker TM; Carolan MG; Ranson M
Oncotarget; 2017 Apr; 8(14):23099-23109. PubMed ID: 28416743
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of urokinase-type plasminogen activator, its receptor, and inhibitors in mouse skin after exposure to a tumor-promoting phorbol ester.
Lund LR; Eriksen J; Ralfkiaer E; Rømer J
J Invest Dermatol; 1996 Apr; 106(4):622-30. PubMed ID: 8617995
[TBL] [Abstract][Full Text] [Related]
17. SerpinB2 deficiency in mice reduces bleeding times via dysregulated platelet activation.
Schroder WA; Le TT; Gardner J; Andrews RK; Gardiner EE; Callaway L; Suhrbier A
Platelets; 2019; 30(5):658-663. PubMed ID: 30388956
[TBL] [Abstract][Full Text] [Related]
18. Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma.
Stabuc B; Markovic J; Bartenjev I; Vrhovec I; Medved U; Kocijancic B
Oncol Rep; 2003; 10(3):635-9. PubMed ID: 12684636
[TBL] [Abstract][Full Text] [Related]
19. Deficiency of Plasminogen Activator Inhibitor Type 2 Limits Brain Edema Formation after Traumatic Brain Injury.
Griemert EV; Hedrich J; Hirnet T; Thal SC
J Neurotrauma; 2019 Jul; 36(14):2272-2278. PubMed ID: 30755137
[TBL] [Abstract][Full Text] [Related]
20. The urokinase-type plasminogen activator and inhibitors in resectable lung adenocarcinoma.
Zhu C; Jiang L; Xu J; Ren A; Ju F; Shu Y
Pathol Res Pract; 2020 Apr; 216(4):152885. PubMed ID: 32113794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
